A novel and highly pathogenic coronavirus (2019-nCoV) has caused an outbreak in Wuhan 20 city, Hubei province of China since December 2019, and soon spread nationwide and spilled 21 over to other countries around the world. To better understand the initial step of infection at 22 atomic-level, we determined the crystal structure of the 2019-nCoV spike receptor-binding 23 domain (RBD) bound with the cell receptor ACE2 at 2.45 Å resolution. The overall ACE2-24 binding mode of the 2019-nCoV RBD is nearly identical to that of the SARS-CoV RBD, which 25 also utilizes ACE2 as the cell receptor. Structural analysis identified residues in 2019-nCoV 26 RBD critical for ACE2 binding, and majority of which are either highly conserved or shared 27 similar side chain properties with those in the SARS-CoV RBD. Such similarity in structure 28 and sequence strongly argue for a convergent evolution between 2019-nCoV and SARS-CoV 29 RBD for improved binding to ACE2 despite of being segregated in different genetic lineages 30 in the betacoronavirus genus. The epitopes of two SARS-CoV antibodies targeting the RBD 31 are also analyzed with the 2019-nCoV RBD, providing insights into future identification of 32 cross-reactive antibodies. 33
The emergence of a novel and highly pathogenic coronavirus (2019-nCoV) in Wuhan city, 34 Hubei province of China and its rapid international spread has posed a serious global public 35 health emergency [1] [2] [3] . Similar to those infected by pathogenic severe acute respiratory syndrome 36 coronavirus (SARS-CoV) in 2003 and Middle East respiratory syndrome coronavirus CoV) in 2012, patients infected by 2019-nCoV manifested a range of symptoms including dry 38 cough, fever, headache, dyspnea and pneumonia with estimated mortality rate of 2.5% 4-6 . Since 39 the initial outbreak in December of 2019, 2019-nCoV has spread throughout China and to more 40 than twenty other countries worldwide. As of February 17, 2020, 70641 cases in China have 41 been confirmed with the infection while 7264 cases are suspected, and 1772 cases have died. 42
Currently, the epicenter Wuhan and the neighboring cities have been under lockdown to 43 minimize continued spread, and the WHO has announced a Public Health Emergency of 44
International Concern (PHEIC) duo to the rapid and global dissemination of 2019-nCoV. 45 Phylogenetic analysis on the coronavirus genomes has revealed that 2019-nCoV is a 46 new member of the betacoronavirus genus, which includes SARS-CoV, MERS-CoV, bat 47 SARS-related coronaviruses (SARSr-CoV), as well as others identified in humans and diverse 48 animal species [1] [2] [3] 7 . Bat coronavirus RaTG13 appears to be the closest relative of the 2019-49 nCoV sharing over 93.1% homology in the spike (S) gene. SARS-CoV and other SARSr-CoVs 50 however are rather distinct with less than 80% homology 1 . 51
Coronaviruses utilize the homotrimeric spike glycoprotein (S1 subunit and S2 subunit 52 in each spike monomer) on the envelope to bind their cellular receptors. Such binding triggers 53 a cascade events leading to the fusion between cell and viral membranes for cell entry. Our 54 cryo-EM studies have shown that the binding of SARS-CoV spike to the cell receptor ACE2 55 induces the dissociation of the S1 with ACE2, prompting the S2 to transition from a metastable 56 prefusion to a more stable postfusion state that is essential for membrane fusion 8, 9 . Therefore, 57 binding to ACE2 receptor is a critical initial step for SARS-CoV to entry into the target cells. 58
Recent studies also pointed to the important role of ACE2 in mediating entry of 2019-nCoV 1,10 . 59
HeLa cells expressing ACE2 is susceptible to 2019-nCoV infection while those without failed 60 to do so 1 . In vitro SPR experiments also showed that the binding affinity of ACE2 to the spike 61 glycoprotein and to the receptor-binding domain (RBD) are equivalent, with the former of 14.7 62 nM and the latter of 15.2 nM 11,12 . These results indicate that the RBD is the key functional 63 component within the S1 subunit responsible for binding to ACE2. 64
The cryo-EM structure of the 2019-nCoV spike trimer at 3.5 Å resolution has just been 65 reported 12 . The coordinates are not yet available for detailed characterization. However, 66 inspection of the structure features presented in the uploaded manuscript on bioRxiv indicated 67 incomplete resolution of RBD in the model, particularly for the receptor-binding motif (RBM) 68 that interacts directly with ACE2. Computer modeling of interaction between 2019-CoV RBD 69 and ACE2 has identified some residues potentially involved in the actual interaction but the 70 actual interaction remained elusive 13 . Furthermore, despite of impressive cross-reactive 71 neutralizing activity from serum/plasma of SARS-CoV recovered patients 14 , no SARS-CoV 72 monoclonal antibodies targeted to RBD so far isolated are able to bind and neutralize 2019-73 nCoV 11,12 . These findings highlight some intrinsic sequence and structure differences between 74 the SARS-CoV and 2019-nCoV RBDs. 75
To elucidate the 2019-nCoV RBD and ACE2 interaction at a higher resolution, we 76 chose to determine the complex structure of 2019-nCoV RBD bound with ACE2 by X-ray 77 crystallography. The atomic-level structural information would greatly improve our 78 understanding of interaction between 2019-nCoV and susceptible cells, providing precise 79 target for neutralizing antibodies, and assisting structure-based vaccine design urgently needed 80 in our ongoing combat against 2019-nCoV. Specifically, we expressed the 2019-nCoV RBD 81 (residues Arg319-Phe541) ( Fig. 1a and 1b ) and the N-terminal peptidase domain of ACE2 82 (residues Ser19-Asp615) in Hi5 insect cells and purified them by Ni-NTA affinity and gel-83 filtration (Fig. S1 ). The complex structure was determined by molecular replacement using the 84 SARS-CoV RBD and ACE2 structures as search models, and refined at 2.45 Å resolution to 85
final Rwork and Rfree factors of 21.9% and 27.8%, respectively ( Fig. S2 and Table S1 ). The final 86 model contains residues Cys336 to Glu516 of 2019-nCoV RBD and residues Ser19 to Asp615 87 of ACE2 N-terminal peptidase domain, as well as 63 solvent molecules. 88
The 2019-nCoV RBD has a twisted four-stranded antiparallel β sheet (β1, β2, β3 and 89 β6) with short connecting helices and loops forming as the core ( Fig. 1b and 1c ). Between the 90 β3 and β6 strands in the core, there is an extended insertion containing short β4 and β5 strands, 91 α4 and α5 helices and loops ( Fig. 1b and 1c ). This extended insertion is the receptor-binding 92 motif (RBM) containing most of the contacting residues of 2019-nCoV for ACE2 binding. A 93 total of nine cysteine residues are found in the RBD, six of which forming three pairs of 94 disulfide bonds are resolved in the final model. Among these three pairs, two are in the core 95 (Cys336-Cys361 and Cys379-Cys432) to help stabilize the β sheet structure (Fig. 1c ) while the 96 remaining one (Cys480-Cys488) connects loops in the distal end of the RBM (Fig. 1c ). The N-97 terminal peptidase domain of ACE2 has two lobes, forming the peptide substrate binding site 98 between them. The extended RBM in the 2019-nCoV RBD contacts the bottom side of the 99 ACE2 small lobe, with a concave outer surface in the RBM accommodating the N-terminal 100 helix of the ACE2 (Fig. 1c ). The overall structure of the 2019-nCoV RBD is similar to that of 101 the SARS-CoV RBD ( Fig. 2a) , with an r.m.s.d. of 1.2 Å for 174 aligned Cα atoms. Even in the 102 RBM that has more sequence variations, the overall structure is also highly similar (r.m.s.d. of 103 1.3 Å) with only one obvious conformational change in the distal end ( Fig. 2a ). The overall 104 binding model of the 2019-nCoV RBD to the ACE2 is also nearly identical to that observed in 105 previously determined SARS-CoV RBD/ACE2 complex structure 15 (Fig. 2b) . 106
The cradling of the ACE2 N-terminal helix by the RBM outer surface results in a large 107 buried surface of ~1700 Å 2 between the 2019-nCoV RBD and ACE2 receptor ( Fig. 1c ). With 108 a distance cutoff of 4 Å, a total of 18 residues of the RBD contact 20 residues of the ACE2 109 ( Fig. 3a and Table S2 ). Analysis of interface between SARS-CoV RBD and ACE2 revealed a 110 total of 16 residues of the SARS-CoV RBD contact 20 residues of the ACE2 ( Fig. 3a and Table  111 S2). Among the 20 residues interacting with the two different RBDs, 17 are shared and most 112 of which are located at the N-terminal helix ( Fig. 2a ). One prominent and common feature 113 presented at both interfaces is the networks of hydrophilic interactions. There are 17 hydrogen 114 bonds and 1 salt bridge at the 2019-nCoV RBD/ACE2 interface, and 12 hydrogen bonds and 2 115 salt bridges at the SARS-CoV RBD/ACE2 interface (Table 1) . Another shared feature is the 116 involvement of multiple tyrosine residues in forming hydrogen-bonding interactions with the 117 polar hydroxyl group. These include Tyr449, Tyr489, Tyr495 and Tyr505 from the 2019-nCoV 118 RBD and Tyr436, Tyr475 and Tyr491 from the SARS-CoV RBD (Table 1) . To further identify 119 and compare the ACE2-interacting residues, we used structure-guided sequence alignment and 120 mapped them onto their respective RBD sequences (Fig. 3b ). Among 14 shared amino acid 121 positions utilized by both RBMs for ACE2 interaction, eight have the identical residues 122 between the 2019-nCoV and SARS-CoV RBDs including Tyr449/Tyr436, Tyr453/Tyr440, 123
Asn487/Asn473, Tyr489/Tyr475, Gly496/Gly482, Thr500/Thr486, Gly502/Gly488 and 124 Tyr505/Tyr491 (Fig. 3b ). Five positions have residues demonstrating similar biochemical 125
properties despite of having different side chains including Leu455/Tyr442, Phe456/Leu443, 126 486Phe/Leu472, Gln493/Asn479 and Asn501/Thr487 (Fig. 3b ). Four of the five SARS-CoV 127 residues such as Tyr442, Leu472, Asn479 and Thr487 have previously been shown to be 128 critical for ACE2 binding 13 . The remaining one is at the Gln498/484Tyr position, while the 129 SARS-CoV RBD Tyr484 is not involved in hydrogen-bonding interaction, the Gln498 of the 130 2019-nCoV RBD forms hydrogen-bonding interaction with Gln42 of ACE2 (Table 1) . Outside 131 RBM, there is a unique ACE2-interacting residues Lys417 in the 2019-nCoV, forming a salt-132 bridge with ACE2 Asp30 (Fig. 3b ). This position is replaced by a valine in the SARS-CoV 133 RBD that fails to participate in ACE2 binding (Fig. 3b ). Consistently, comparison of the 134 surface electrostatic potential also identified a positive-charged patch on the 2019-nCoV RBD 135 contributed by Lys417 that is absent on the SARS-CoV RBD (Fig. 3c ). Taken together, these 136 results show that the 2019-nCoV RBD/ACE2 and SARS-CoV RBD/ACE2 interfaces share 137 substantial similarity in the buried surface area, the number of interacting residues, and 138 hydrophilic interaction networks although some differences in surface electrostatic potential 139 were identified (Fig. 3) . Such similarity argues strongly for the convergent evolution of the 140 2019-nCoV and SARS-CoV RBD structures to improve binding affinity to the same ACE2 141 receptor despite of being in different genetic lineages in the betacoronavirus genus. 142
Consistent with structural similarity, the binding affinities between ACE2 and 2019-143 nCoV and SARS-CoV RBDs also fall into the same range (~10-60 nM) as previously 144 reported 11,12 . However, this is somewhat different from a recent report where an ~10-20 fold 145 increased binding between ACE2 and 2019-nCoV spike trimer was found (KD of 14.7 nM) 146 compared with that between ACE2 and SARS-CoV RBD-SD1 (KD of 325 nM) 12 . This is 147 perhaps due to the different proteins used in the assay or some other unknown reasons. 148
Nevertheless, the binding affinity alone is unlikely to explain the unusual transmissibility of 149 2019-nCoV. Other factors such as the unique "RRAR" furin cleavage site at the S1/S2 150 boundary of the 2019-nCoV spike may play more important roles in facilitating the rapid 151 human-to-human transmission. also raised the hope of rapid application of previously characterized SARS-CoV monoclonal 157 antibodies in the clinical setting. However, no antibody targeted to SARS-CoV (m396, S230, 158 80R and CR3014) has so far demonstrated any impressive cross-binding and neutralization 159 activity against 2019-nCoV spike or RBD 11, 12, [16] [17] [18] [19] . One exception is SARS-CoV antibody 160 CR3022 that binds to the 2019-nCoV RBD with a KD of 6.2 nM, although its neutralizing 161 activity against 2019-nCoV has not been reported yet 11 . Currently, we are uncertain where 162 exactly the epitope of CR3022 on SARS-CoV nor on 2019-nCoV RBDs. Among the three 163 antibodies incapable of binding to the 2019-nCoV RBD, two (m396 and 80R) have the epitopes 164 resolved by high resolution crystal structure determination of SARS-CoV RBD-Fab complexes. 165
Through mapping these epitope residues onto the sequence of SARS-CoV RBD aligned with 166 the sequence of 2019-nCoV RBD (Fig. 4) , we found that antibody m396 has seven residue 167 changes in the 2019-nCoV RBD among 21 epitope positions (Fig. 4 ). There are 15 reside 168 changes in the 2019-nCoV RBD among 24 epitope positions by antibody 80R (Fig. 4) . This 169 may provide the structural basis for the lack of cross-reactivity by m396 and 80R. However, 170 conserved residues between 2019-nCoV and SARS-nCoV RBD indeed exist, even in the more 171 variable RBM (Fig. 4) . The cross-neutralization of 2019-nCoV by horse anti-SARS-CoV 172 serum and serum/plasm from recovered SARS patients indicates a great potential in identifying 173 antibodies with cross-reactivity between these two coronaviruses 1,14 . Such antibody will 174 present a great promise for developing therapeutic agents toward diverse coronavirus species 175 including 2019-nCoV. 176 177
Materials and Methods 178

Protein expression and purification 179
The 2019-nCoV receptor-binding domain (RBD) and the N-terminal peptidase domain of 180 human ACE2 were expressed using the Bac-to-Bac baculovirus system (Invitrogen). The 2019-181 nCoV RBD (residues Arg319-Phe541) with an N-terminal gp67 signal peptide for secretion 182 and a C-terminal 6×His tag for purification was inserted into pFastBac-Dual vector (Invitrogen). 183
The construct was transformed into bacterial DH10Bac component cells, and the extracted 184 bacmid was then transfected into Sf9 cells using Cellfectin II Reagent (Invitrogen). The low-185 titer viruses were harvested and then amplified to generate high-titer virus stock, which was 186 used to infect Hi5 cells at a density of 2×10 6 cells/ml. The supernatant of cell culture containing 187 the secreted RBD was harvested 60 h after infection, concentrated and buffer-exchanged to 188 HBS (10 mM HEPES, pH 7.2, 150 mM NaCl). RBD was captured by Ni-NTA resin (GE 189
Healthcare) and eluted with 500 mM imidazole in HBS buffer. RBD was then purified by gel 190 filtration chromatography using the Superdex 200 column (GE Healthcare) pre-equilibrated 191 with HBS buffer. Fractions containing RBD were collected. 192
The N-terminal peptidase domain of human ACE2 (residues Ser19-Asp615) was 193 expressed and purified by essentially the same protocol used for the 2019-nCoV RBD. To 194 purify the 2019-nCoV RBD/ACE2 complex, ACE2 was incubated with RBD for 1 h on ice in 195 HBS buffer, and the mixture was then subjected to gel filtration chromatography. Fractions 196 containing the complex were pooled and concentrated to 13 mg/ml. 197
Crystallization and data collection 198
Crystals were successfully grown at room temperature in sitting drops, over wells containing 199 100 mM MES, pH 6.5, 10% PEG5000mme, 12% 1-propanol. The drops were made by mixing 200 200 nL RBD/ACE2 in 20 mM Tris pH 7.5, 150 mM NaCl with 200 nL well solution. Crystals 201 were harvested, soaked briefly in 100 mM MES, pH 6.5, 10% PEG5000mme, 12% 1-propanol, 202 20% glycerol, and flash-frozen in liquid nitrogen. Diffraction data were collected at the BL17U 203 beam line of the Shanghai Synchrotron Research Facility (SSRF) 20 . Diffraction data were auto-204 processed with aquarium pipeline and the data processing statistics are listed in Table S1 21 . 205
Structural determination and refinement 206
The structure was determined by the molecular replacement method with PHASER in CCP4 207 suite 22 . The search models are ACE2 extracellular domain and SARS-CoV RBD (PDB code 208 2AJF). Density map improvement by atoms update and refinement was performed with 209 ARP/wARP 23 . Subsequent model building and refinement were performed using COOT and 210 PHENIX, respectively 24, 25 . The structural refinement statistics are listed in Table S1 . All 211 structural figures were generated with PyMol 26 . 212 213 Acknowledgments 214
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